FDA Webview
X
about-us-banner

FDA Related News

Home / Articles / FDA Related News
Federal Register

CDER Seeking Input on Study Data Template

Federal Register notice: CDER seeks comments on a proposed Analysis Data Reviewers Guide (ADRG) template that was developed under an ongoing collabora...

Ad Group Refers Synergy Claims to FTC

The Better Business Bureaus National Advertising Division says Synergy Pharmaceuticals declined to participate in a self-regulatory proceeding to reso...

Human Drugs

Drug Companies Greater Use of Real-World Evidence: Report

A Tufts Center for the Study of Drug Development company survey finds that use of real-world evidence is increasing and will grow even more in the nex...

Device Recalls Down, Drug Recalls Up in 3rd Quarter

Stericycles third quarter 2017 recall index says medical device recalls fell, while drug recalls increased.

Federal Register

Guide on Recurrent Herpes Labialis Drug Development

Federal Register notice: FDA makes available a guidance on Recurrent Herpes Labialis (RHL): Developing Drugs for Treatment and Prevention.

Federal Register

Proposed Info Collection on Target Product Profile Guide

Federal Register notice: FDA submits to OMB a new proposed information collection supporting its Draft Guidance for Industry and Review Staff on Targe...

Federal Register

Comments Sought on Info Collection for Expedited Product Programs

Federal Register notice: FDA seeks comments on an information collection revision for its Guidance for Industry on Expedited Programs for Serious Cond...

Human Drugs

Adverse Reports from United Pharmacy Injectable

FDA says it has investigated two adverse event results from a United Pharmacy compounded glutamine, arginine, and carnitine product.

Human Drugs

FDA OKs Expanded Abuse Deterrent Claims for Xtampza

FDA approves a Collegium Pharmaceutical supplemental NDA to enhance the label for Xtampza ER (oxycodone extended-release), an abuse-deterrent, extende...

Human Drugs

Courts Should Defer to FDA Pediatric Policy: Professor

A Yale Law School professor says court should back FDAs denial of pediatric exclusivity for Amgens Sensipar because one of the companys studies failed...